FEC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, followed by pertuzumab, trastuzumab and docetaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.

**Synonyms:** - FEC Followed by Docetaxel/Trastuzumab/Pertuzumab - FEC Followed by Pertuzumab + Trastuzumab + Docetaxel - FEC-THP (Docetaxel) - FEC-THP (Docetaxel) (trastuzumab-anns) - FEC-THP (Docetaxel) (trastuzumab-dkst) - FEC-THP (Docetaxel) (trastuzumab-dttb) - FEC-THP (Docetaxel) (trastuzumab-herw) - FEC-THP (Docetaxel) (trastuzumab-pkrb) - FEC-THP (Docetaxel) (trastuzumab-qyyp) - FEC-THP (Docetaxel) (trastuzumab-strf) - FEC-THP (Docetaxel) (trastuzumab-zerc) - Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Docetaxel - Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Docetaxel